ENTITY
Innovent Biologics Inc

Innovent Biologics Inc (1801 HK)

382
Analysis
Health CareChina
Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.
more
10 Dec 2018 20:12

Junshi Biosciences IPO Valuation: Sensibly Priced with Upside at the Low-End

Shanghai Junshi Bioscience Co. Ltd. (1387344D CH) launched its Hong Kong IPO today. The mid-point of Junshi's IPO price range of HK$19.38-20.38 per...

Logo
516 Views
Share
bullishTencent Music
08 Dec 2018 18:42

Last Week's GER IPO Research: Tencent Music, Softbank, Weimob, Luzhou, Junshi, Yancoal and Asiainfo

We had another busy week for IPO research the GER team. This week, we recommend participating in the Tencent Music Entertainment (TME US) IPO,...

Logo
502 Views
Share
03 Dec 2018 10:11

Junshi Bioscience (君实医药) IPO: Thoughts on Valuation (Part 2)

Shanghai Junshi Biosciences, a China-based biotechnology company listed on the NEEQ market (ticker 833330.NEEQ) with a market capitalization of USD...

Logo
656 Views
Share
bearishWuXi AppTec
03 Dec 2018 08:47

Last Week in GER IPO Research: Wuxi, Mobvista, Yancoal, IDreamSky, Mogu, Asiainfo, Softbank & More!

Last week was a busy week for IPO content. In this edition, we highlight a differentiated AH premium piece on pharma outsourcer WuXi AppTec Co....

Logo
406 Views
Share
03 Dec 2018 08:00

Junshi Biosciences IPO Preview: A Sense of Déjà Vu Without the Excitement

Shanghai Junshi Bioscience Co. Ltd. (1387344D CH) is a biopharmaceutical company which is developing a pipeline of 13 biologic drugs, including...

Logo
420 Views
Share
x